Sign in Sign up for free

Last updated: 5 August 2021 at 5:25pm EST

Simon Pedder Net Worth




The estimated Net Worth of Simon Pedder is at least $913 Thousand dollars as of 27 August 2019. Simon Pedder owns over 6,734 units of Athenex Inc stock worth over $52,547 and over the last 10 years he sold ATNX stock worth over $0. In addition, he makes $860,546 as Chief Business and Strategy Officer - Proprietary Products at Athenex Inc.

Simon Pedder ATNX stock SEC Form 4 insiders trading

Simon has made over 4 trades of the Athenex Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 6,734 units of ATNX stock worth $20,067 on 27 August 2019.

The largest trade he's ever made was buying 13,300 units of Athenex Inc stock on 20 August 2014 worth over $49,875. On average, Simon trades about 1,378 units every 87 days since 2014. As of 27 August 2019 he still owns at least 262,734 units of Athenex Inc stock.

You can see the complete history of Simon Pedder stock trades at the bottom of the page.





Simon Pedder biography

Dr. Simon C. Pedder Ph.D. serves as Chief Business and Strategy Officer - Proprietary Products of the Company. Dr. Pedder joined our company as Chief Business Development Officer in February 2016 and now serves as our Chief Business and Strategy Officer for Proprietary Products. Dr. Pedder has had a long career in both drug development and commercialization. This includes recent leadership roles with publicly traded biotechnology companies. He was President and CEO of Cellectar Biosciences from April 2014 to June 2015. He was President and CEO of Chelsea Therapeutics from May 2004 to July 2012. Previously he was Vice President of Oncology Pharma Business, and a company officer at Hoffmann-La Roche, as well he has served as the Life Cycle Leader and Global Project Leader of Pegasys/IFN and Head of Hepatitis Franchise at Roche. Dr. Pedder has served on the board of directors of Cerecor, Inc. since April 2018. Formerly, he served on the board of directors of Mateon Therapeutics, Inc. from March 2016 to April 2019 and Delcath Systems, Inc. from November 2017 to April 2019. Dr. Pedder has served as a member of the faculty in the Department of Pharmacology in College of Medicine in the University of Saskatchewan, where he obtained his Ph.D in Pharmacology. During his longstanding career in pharmaceutical development, Dr. Pedder has led the late stage development and commercial launch of multiple proprietary pharmaceutical products. In addition to his Ph.D in Pharmacology, Dr. Pedder obtained a Master of Science in Toxicology from Concordia University, a Bachelor of Science in Environmental Studies from the University of Waterloo, and completed the Roche-sponsored Pharmaceutical Executive Management Program at Columbia Business School.

What is the salary of Simon Pedder?

As the Chief Business and Strategy Officer - Proprietary Products of Athenex Inc, the total compensation of Simon Pedder at Athenex Inc is $860,546. There are 4 executives at Athenex Inc getting paid more, with Johnson Lau having the highest compensation of $4,483,840.



How old is Simon Pedder?

Simon Pedder is 59, he's been the Chief Business and Strategy Officer - Proprietary Products of Athenex Inc since 2019. There are 10 older and 6 younger executives at Athenex Inc. The oldest executive at Athenex Inc is John Vierling, 74, who is the Independent Director.

What's Simon Pedder's mailing address?

Simon's mailing address filed with the SEC is C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO, NY, 14203.

Insiders trading at Athenex Inc

Over the last 7 years, insiders at Athenex Inc have traded over $33,215,399 worth of Athenex Inc stock and bought 5,920,005 units worth $73,651,360 . The most active insiders traders include Advisors Llcperceptive Life..., Song Yi Zhang, and Song Yi Mandra Medical Ltd .... On average, Athenex Inc executives and independent directors trade stock every 12 days with the average trade being worth of $10,843. The most recent stock trade was executed by Joe Annoni on 22 February 2023, trading 625 units of ATNX stock currently worth $125.



What does Athenex Inc do?

athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.



What does Athenex Inc's logo look like?

Athenex Inc logo

Complete history of Simon Pedder stock trades at Athenex Inc, Cellectar Biosciences Inc, and Cerecor Inc

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
27 Aug 2019 CERC Cerecor Inc Simon Pedder
Executive Chairman of the Bd
 Buy 6,734 $2.98 $20,067
27 Aug 2019
262,734 ↗
14 May 2019 CERC Cerecor Inc Simon Pedder
Executive Chairman of the Bd
 Buy 6,000 $5.06 $30,360
14 May 2019
6,000 ↗
14 Nov 2018 ATNX Athenex Inc Simon Pedder
See Remarks
 Buy 2,908 $10.26 $29,836
14 Nov 2018
3,908 ↗
20 Aug 2014 CLRB Cellectar Biosciences Inc Simon Pedder
President and CEO
 Buy 13,300 $3.75 $49,875
20 Aug 2014
13,300 ↗


Athenex Inc executives and stock owners

Athenex Inc executives and other stock owners filed with the SEC include: